Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm.
We sought to clarify the role of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). We retrospectively identified 25 BPDCN patients (allo-HSCT, n = 14; auto-HSCT, n = 11) from registry data of the Japan Society for Hematopoietic Cell Transplantation and analyzed clinicopathologic data and clinical outcomes after transplantation. The median age at HSCT was 58 years (range, 17-67 years). All 11 patients who underwent auto-HSCT were in the first complete remission (CR1). With a median follow-up of 53.5 months, the overall survival rates at 4 years for patients who underwent auto-HSCT and allo-HSCT were 82% and 53% (P = .11), respectively, and progression-free survival rates were 73% and 48% (P = .14), respectively. Auto-HSCT for BPDCN in CR1 appears to provide promising results and deserves further evaluation in the setting of prospective trials.
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Hematology and Oncology.
Tomohiro
http://orcid.org/0000-0001-6782-8361
T
Aoki
Department of Medical Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan;
Ritsuro
R
Suzuki
Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan;
Yachiyo
Y
Kuwatsuka
Department of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan;
Shinichi
S
Kako
Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;
Katsuya
K
Fujimoto
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;
Jun
J
Taguchi
Department of Hematology and Oncology, Kyoto University Hospital, Kyoto, Japan;
Tadakazu
T
Kondo
Department of Cellular Transplantation Biology, Kanazawa University, Graduate School of Medical Sciences, Kanazawa, Japan;
Kinya
K
Ohata
Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan;
Toshiro
T
Ito
Department of Hematology, Tenri Hospital, Tenri, Japan;
Yoshimasa
Y
Kamoda
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;
Takahiro
T
Fukuda
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;
Tatsuo
T
Ichinohe
Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan;
Kengo
K
Takeuchi
Department of Hematology, Toranomon Hospital, Tokyo, Japan; and.
Koji
K
Izutsu
Cancer Center, Shimane University Hospital, Izumo, Japan.
Junji
J
Suzumiya
D000293:Adolescent; D000328:Adult; D000368:Aged; D064592:Autografts; D003713:Dendritic Cells / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010954:Plasmacytoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate